TATTON: Phase 1b trial of AZD9291 combined with MEDI4736, savolitinib or selumetinib in EGFR-mutant lung cancer | Dr Geoffrey Oxnard at Annual Meeting 2015 - 101271

Spotlight
Video

TATTON: Phase 1b trial of AZD9291 combined with MEDI4736, savolitinib or selumetinib in EGFR-mutant lung cancer | Dr Geoffrey Oxnard at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results of the multi-arm phase 1 TATTON trial, which evaluated the mutant-selective EGFR tyrosine kinase inhibitor, AZD9291, combined with MEDI4736 (anti-PD-L1 monoclonal antibody), savolitinib (MET inhibitor) or selumetinib (MEK1/2 inhibitor) in patients with EGFR-mutant lung cancer.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/30/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.